Skip to main content
70°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relay Therapeutics Inc
(NQ:
RLAY
)
7.475
+0.075 (+1.01%)
Streaming Delayed Price
Updated: 2:18 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relay Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
The global
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
The global
Via
Talk Markets
Expert Ratings For Relay Therapeutics
June 07, 2024
Via
Benzinga
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
June 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Key Takeaways From Relay Therapeutics Analyst Ratings
May 10, 2024
Via
Benzinga
Relay Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
June 05, 2024
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...
Via
Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics's Earnings: A Preview
February 21, 2024
Via
Benzinga
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 13, 2024
Company to disclose new programs from existing unnamed pre-clinical pipeline
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
5 Of 7 AI Categories Rose, Slightly,Over Past Week
May 11, 2024
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 7 AI Categories Declined, On Average, The First Week Of May
May 05, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
April 25, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
April 11, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
AI Surge Ending: Only One Category Was Up This Week
April 06, 2024
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
March 15, 2024
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities.
Via
InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
February 26, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
February 22, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
February 15, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.